COO

COO

Cooper Companies (The)

$58.16

+0.38% Oct 19 close

Health CareS&P 500 Compare

1M 3M 6M 1Y 2Y

COOSPY

+4.7%

+5.2%

-18.8%

-16.3%

YTD

-29.0%

-19.2%

Live chart

Loading live chart…

What they do

The Cooper Companies, Inc. develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia.

Healthcare · Medical Instruments & Supplies

For information only · Important disclosures

Grades vs sector

Momentum

16th percentile in sector

D-

12-1 return: -19.1%
Percentile within its GICS sector across the S&P 1500.

Growth

13th percentile in sector

D-

Revenue growth (YoY): +0.6%
Percentile within its GICS sector across the S&P 1500.

Value

67th percentile in sector

Forward E/P: 8.1% · EBITDA/EV: 6.8%
Percentile within its GICS sector across the S&P 1500.

Profitability

54th percentile in sector

C+

Profit margin: +13.5% · Return on equity: +6.8%
Percentile within its GICS sector across the S&P 1500.

Revisions

Not enough data yet

–

EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 5 live models right now.

Quality Growth

Outside this model's universe or screens

Momentum Top 15

ranked 315 of 499 · 12-month momentum 2.2%

Momentum Blend

Not in the current book

New Highs Growth

Outside this model's universe or screens

Coteau Long Book

Not in the current book

News

More news

3 S&P 500 Stocks We Find Risky

StockStory · Oct 20

Key stats

52-week range$53.27 – $84.32

Valuation and fundamentals

Valuation & fundamentals

Bottom line

Roughly fairly valued

Model read-out from the numbers below, not advice. Score +0 (DCF counts double).

•DCF (base case)below the price by 3%

•Piotroski F-score6/9

•Net debt / EBITDA3.0x

Discounted cash flow

Bear

$30

-48%

growth 2% · disc. 10.2% · term. 2.0%

Base

$56

-3%

growth 7% · disc. 9.2% · term. 2.5%

Bull

$92

+59%

growth 10% · disc. 8.2% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal

Not enough data to run a reverse DCF.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-07-31). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)

sector median 29.9×

–

Forward P/E

sector median 17.6×

–

EV / EBITDA

sector median 15.8×

–

Price / sales

sector median 3.1×

–

Price / book

sector median 3.5×

–

FCF yield

sector median 4.1%

–

Quality & financial health

Gross margin

65.9%

Operating margin

12.8%

FCF margin

16.0%

Net margin

13.5%

Return on equity

6.8%

Return on invested capital

4.9%

Net debt / EBITDA

3.0×

Current ratio

1.2×

Interest cover

6.1×

Cash conversion (OCF/NI)

1.8×

Piotroski F-score 6/9 · last two fiscal years

✓ Positive net income✓ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✓ No share dilution✗ Gross margin improved✓ Asset turnover improved

Analysts

No analyst targets available.

Annual history

FY	Revenue	Net income	Free cash flow
2025	$4.1B	$374.9M	$433.7M
2024	$3.9B	$392.3M	$288.1M
2023	$3.6B	$294.2M	$215.0M
2022	$3.3B	$385.8M	$450.4M
2021	$2.9B	$2.9B	$524.2M
2020	$2.4B	$238.4M	$176.2M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +7.3%.

Earnings

Next report: –

No EPS history available.

Stats refreshed – ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

coteau

Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app

Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.

How it works Disclaimer Terms Privacy Data status Send feedback

Beta 0.9 · Oct 21, 2026